FY2024 EPS Estimates for Elutia Boosted by Cantor Fitzgerald

Elutia Inc. (NASDAQ:ELUT) – Equities researchers at Cantor Fitzgerald increased their FY2024 earnings estimates for Elutia in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings per share of ($1.74) for the year, up from their previous estimate of ($1.76). Cantor Fitzgerald currently has a “Overweight” rating and a $10.00 target price on the stock. The consensus estimate for Elutia’s current full-year earnings is ($1.76) per share.

Elutia Stock Performance

Shares of NASDAQ ELUT opened at $3.22 on Thursday. The stock’s 50 day moving average price is $3.88 and its two-hundred day moving average price is $3.81. Elutia has a 52-week low of $2.28 and a 52-week high of $5.24.

Institutional Investors Weigh In On Elutia

A number of institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in Elutia by 50.3% in the third quarter. Geode Capital Management LLC now owns 188,408 shares of the company’s stock worth $718,000 after purchasing an additional 63,047 shares during the period. Nantahala Capital Management LLC lifted its position in shares of Elutia by 8.8% in the 2nd quarter. Nantahala Capital Management LLC now owns 1,795,697 shares of the company’s stock worth $8,907,000 after buying an additional 145,697 shares during the last quarter. Arcus Capital Partners LLC boosted its holdings in shares of Elutia by 100.0% in the 3rd quarter. Arcus Capital Partners LLC now owns 20,000 shares of the company’s stock valued at $76,000 after buying an additional 10,000 shares during the period. Renaissance Technologies LLC grew its position in shares of Elutia by 50.5% during the 2nd quarter. Renaissance Technologies LLC now owns 53,616 shares of the company’s stock valued at $266,000 after buying an additional 18,000 shares during the last quarter. Finally, Perkins Capital Management Inc. raised its stake in Elutia by 9.8% during the third quarter. Perkins Capital Management Inc. now owns 856,552 shares of the company’s stock worth $3,263,000 after acquiring an additional 76,450 shares during the period. 74.03% of the stock is currently owned by institutional investors.

Elutia Company Profile

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.